ChromaCode Selected as a Winner of $6M XPRIZE Rapid COVID Testing Competition
March 16, 2021ChromaCode’s Emergency Use Authorization (EUA) Expanded by FDA for High-Throughput HDPCR™ SARS-CoV-2 Real-Time PCR Assay
February 23, 2022Carlsbad, Calif. August 11, 2021 – ChromaCode, Inc., a company that combines data science and proprietary reagents to improve clinical molecular analysis, today announced that Patrick Balthrop, Sr. and Kevin O’Boyle have joined the company’s Board of Directors.
Mr. Balthrop is the former CEO and President of Luminex, a pioneer in multiplexed diagnostics platform development; chairman of the Board at Agendia, Inc, a molecular diagnostic company focused on oncology diagnostics for breast cancer; chairman of Discovery Life Sciences, a world leader in biospecimen and biomarker services; and a founding principal of Apalachee Ventures, LLC.
Mr. O’Boyle was most recently Chairman of the Board of Directors at GenMark Diagnostics, a leading provider of sample-to-answer molecular diagnostic solutions acquired by Roche in March, 2021; and is currently a member of the Board of Directors at Nevro and Sientra.
“We are expanding the Board to include long-tenured leadership in our targeted markets” said ChromaCode’s CEO and co-founder, Greg Gosch. “Pat’s and Kevin’s breadth of expertise will be invaluable as we expand our footprint in oncology, reproductive health and infectious disease using our HDPCR™ technology.”
Alex Dickinson, ChromaCode’s Executive Chairman and co-founder commented, “We are very fortunate to welcome Pat and Kevin to the board and look forward to benefiting from their vast experience in molecular diagnostics. Their expertise adds a wealth of industry know-how and will support execution of our long-term strategy.”
About ChromaCode
ChromaCode is a diagnostic company providing proprietary reagents with scalable cloud analytics to dramatically improve clinical molecular analysis. The company’s unique core of data scientists and molecular biologists leverages patented mathematical methods and algorithms to extract new information from biochemistry reactions. This approach substantially increases the performance capabilities of today’s gold-standard molecular diagnostics instruments at a very low cost. For more information, visit ChromaCode.com
Media Contact
CG Life – Blair Ciecko
bciecko@cglife.com